日前(qian),停(ting)牌多日的(de)天(tian)(tian)壇生物發(fa)布(bu)了(le)重(zhong)(zhong)大資(zi)產重(zhong)(zhong)組繼續停(ting)牌公(gong)(gong)(gong)告,公(gong)(gong)(gong)司(si)介紹,目前(qian)本次重(zhong)(zhong)大資(zi)產重(zhong)(zhong)組的(de)交易(yi)方(fang)(fang)式仍(reng)在籌劃中,初步方(fang)(fang)案擬為(wei)公(gong)(gong)(gong)司(si)向控股(gu)(gu)股(gu)(gu)東購買資(zi)產,交易(yi)方(fang)(fang)式為(wei)現金;同時控股(gu)(gu)股(gu)(gu)東將其下屬經(jing)營血液制品業務資(zi)產以(yi)作價入(ru)股(gu)(gu)天(tian)(tian)壇生物控股(gu)(gu)子(zi)公(gong)(gong)(gong)司(si)成都蓉生藥業有(you)限責任公(gong)(gong)(gong)司(si)等方(fang)(fang)式轉入(ru)上市公(gong)(gong)(gong)司(si)。
國信證券(quan)認為(wei),天壇(tan)生物自10月份開始以重(zhong)大資產(chan)重(zhong)組為(wei)由,一(yi)直(zhi)處于停牌狀態,三(san)大所注入(ru)進入(ru)關鍵時期。三(san)大所整合完成(cheng)后天壇(tan)生物將成(cheng)為(wei)中國第一(yi)大也是唯一(yi)的(de)血制品國家隊,提效(xiao)、擴(kuo)漿(jiang)源等業務工作將重(zhong)新成(cheng)為(wei)最主要任務。
據《證券日(ri)報(bao)》記者了(le)解,如若完成資產重組(zu),天壇生(sheng)物十三五期間的采漿量(liang)目標有望超過2000噸,成為行業采漿量(liang)第一,成為名副(fu)其實的血制品航母公司(si)。
解決同業競爭時間迫近
2016年2月(yue)份,天壇(tan)生(sheng)(sheng)(sheng)物(wu)(wu)控(kong)股(gu)股(gu)東中(zhong)(zhong)國(guo)(guo)生(sheng)(sheng)(sheng)物(wu)(wu)作(zuo)出《關(guan)于(yu)與北(bei)京天壇(tan)生(sheng)(sheng)(sheng)物(wu)(wu)制(zhi)品(pin)股(gu)份有限(xian)(xian)公(gong)(gong)司之間同(tong)業(ye)(ye)競(jing)爭情況(kuang)的(de)承諾》:“中(zhong)(zhong)國(guo)(guo)生(sheng)(sheng)(sheng)物(wu)(wu)將積(ji)極致力于(yu)所(suo)屬(shu)企業(ye)(ye)的(de)業(ye)(ye)務(wu)整合(he)工(gong)作(zuo),目前已經(jing)確(que)定了將天壇(tan)生(sheng)(sheng)(sheng)物(wu)(wu)打造為中(zhong)(zhong)國(guo)(guo)生(sheng)(sheng)(sheng)物(wu)(wu)下(xia)屬(shu)唯一的(de)血液(ye)制(zhi)品(pin)業(ye)(ye)務(wu)平臺(tai)的(de)基(ji)本方案,即將下(xia)屬(shu)經(jing)營血液(ye)制(zhi)品(pin)業(ye)(ye)務(wu)的(de)主要資(zi)(zi)產以(yi)作(zuo)價入股(gu)天壇(tan)生(sheng)(sheng)(sheng)物(wu)(wu)控(kong)股(gu)子公(gong)(gong)司成都蓉生(sheng)(sheng)(sheng)藥業(ye)(ye)有限(xian)(xian)責任公(gong)(gong)司等(deng)方式轉(zhuan)入上(shang)(shang)市(shi)公(gong)(gong)司,同(tong)時,天壇(tan)生(sheng)(sheng)(sheng)物(wu)(wu)將把下(xia)屬(shu)經(jing)營疫苗資(zi)(zi)產業(ye)(ye)務(wu)的(de)相(xiang)關(guan)資(zi)(zi)產的(de)控(kong)制(zhi)權轉(zhuan)移給中(zhong)(zhong)國(guo)(guo)生(sheng)(sheng)(sheng)物(wu)(wu)。中(zhong)(zhong)國(guo)(guo)生(sheng)(sheng)(sheng)物(wu)(wu)承諾于(yu)2018年3月(yue)15日之前消(xiao)除所(suo)屬(shu)企業(ye)(ye)(除天壇(tan)生(sheng)(sheng)(sheng)物(wu)(wu)以(yi)外)與天壇(tan)生(sheng)(sheng)(sheng)物(wu)(wu)之間的(de)同(tong)業(ye)(ye)競(jing)爭,從(cong)而(er)更加規(gui)范上(shang)(shang)市(shi)公(gong)(gong)司的(de)運作(zuo),更好地保護廣大中(zhong)(zhong)小投資(zi)(zi)者的(de)利(li)益。”
截至(zhi)今年(nian)11月19日,中生生物解(jie)決其與(yu)天(tian)壇生物存在的同業(ye)競爭事(shi)宜距離截止(zhi)日期僅剩(sheng)不到四個月。
截至目前,天壇生(sheng)物(wu)已(yi)經(jing)通(tong)過實施(shi)重大資產(chan)重組將疫(yi)苗制(zhi)(zhi)品(pin)(pin)(pin)業(ye)務(wu)的相關資產(chan)全部轉移給中國(guo)生(sheng)物(wu),徹(che)底(di)解決(jue)了公(gong)司(si)與控(kong)(kong)股(gu)(gu)股(gu)(gu)東之間(jian)在(zai)疫(yi)苗制(zhi)(zhi)品(pin)(pin)(pin)業(ye)務(wu)方(fang)面的同(tong)業(ye)競(jing)爭問題。中國(guo)生(sheng)物(wu)下屬子公(gong)司(si)蘭州生(sheng)物(wu)制(zhi)(zhi)品(pin)(pin)(pin)研究所(suo)(suo)有(you)(you)限責任(ren)公(gong)司(si)、上海(hai)生(sheng)物(wu)制(zhi)(zhi)品(pin)(pin)(pin)研究所(suo)(suo)有(you)(you)限責任(ren)公(gong)司(si)、武漢生(sheng)物(wu)制(zhi)(zhi)品(pin)(pin)(pin)研究所(suo)(suo)有(you)(you)限責任(ren)公(gong)司(si)仍從(cong)事部分血(xue)液制(zhi)(zhi)品(pin)(pin)(pin)業(ye)務(wu),公(gong)司(si)與控(kong)(kong)股(gu)(gu)股(gu)(gu)東在(zai)血(xue)液制(zhi)(zhi)品(pin)(pin)(pin)業(ye)務(wu)方(fang)面的同(tong)業(ye)競(jing)爭尚(shang)未完全消(xiao)除。
天壇生(sheng)(sheng)物(wu)(wu)介紹(shao),為徹底(di)解決(jue)血(xue)液制(zhi)(zhi)品(pin)(pin)業(ye)(ye)務方(fang)面(mian)的(de)同業(ye)(ye)競爭問題,履行上述同業(ye)(ye)競爭承諾,本次交(jiao)(jiao)易標的(de)資產初步(bu)(bu)確(que)(que)定包括中(zhong)國生(sheng)(sheng)物(wu)(wu)下(xia)屬(shu)經營血(xue)液制(zhi)(zhi)品(pin)(pin)業(ye)(ye)務資產。本次重(zhong)大(da)資產重(zhong)組的(de)交(jiao)(jiao)易對(dui)方(fang)初步(bu)(bu)確(que)(que)定為公(gong)司控股股東(dong)中(zhong)國生(sheng)(sheng)物(wu)(wu)以(yi)及中(zhong)國生(sheng)(sheng)物(wu)(wu)的(de)下(xia)屬(shu)子公(gong)司蘭州生(sheng)(sheng)物(wu)(wu)制(zhi)(zhi)品(pin)(pin)研究(jiu)所有限責(ze)任公(gong)司、上海生(sheng)(sheng)物(wu)(wu)制(zhi)(zhi)品(pin)(pin)研究(jiu)所有限責(ze)任公(gong)司和武漢生(sheng)(sheng)物(wu)(wu)制(zhi)(zhi)品(pin)(pin)研究(jiu)所有限責(ze)任公(gong)司,本次交(jiao)(jiao)易構成關聯交(jiao)(jiao)易。
天壇生物表示(shi),由于本次重大資(zi)產重組(zu)涉(she)及標的資(zi)產構(gou)成情況較為(wei)復雜,交易對方(fang)(fang)及資(zi)產范圍等重大事項(xiang)尚未(wei)最終確定,具體(ti)交易方(fang)(fang)案論證及各中介(jie)機構(gou)相關工作尚未(wei)最終完成,故(gu)無法按期(qi)復牌。
中(zhong)(zhong)(zhong)(zhong)證(zheng)網(wang)(wang)聲(sheng)明(ming):凡本(ben)網(wang)(wang)注(zhu)(zhu)明(ming)“來源:中(zhong)(zhong)(zhong)(zhong)國證(zheng)券報(bao)·中(zhong)(zhong)(zhong)(zhong)證(zheng)網(wang)(wang)”的(de)所有作(zuo)品,版權(quan)均屬(shu)于(yu)中(zhong)(zhong)(zhong)(zhong)國證(zheng)券報(bao)、中(zhong)(zhong)(zhong)(zhong)證(zheng)網(wang)(wang)。中(zhong)(zhong)(zhong)(zhong)國證(zheng)券報(bao)·中(zhong)(zhong)(zhong)(zhong)證(zheng)網(wang)(wang)與(yu)作(zuo)品作(zuo)者聯合聲(sheng)明(ming),任何組織未經中(zhong)(zhong)(zhong)(zhong)國證(zheng)券報(bao)、中(zhong)(zhong)(zhong)(zhong)證(zheng)網(wang)(wang)以及作(zuo)者書面授權(quan)不得(de)轉載(zai)、摘編(bian)或利用(yong)其(qi)(qi)它(ta)方式使用(yong)上(shang)述作(zuo)品。凡本(ben)網(wang)(wang)注(zhu)(zhu)明(ming)來源非中(zhong)(zhong)(zhong)(zhong)國證(zheng)券報(bao)·中(zhong)(zhong)(zhong)(zhong)證(zheng)網(wang)(wang)的(de)作(zuo)品,均轉載(zai)自(zi)其(qi)(qi)它(ta)媒體,轉載(zai)目的(de)在于(yu)更好服(fu)務讀者、傳遞信息之需,并不代(dai)表本(ben)網(wang)(wang)贊同其(qi)(qi)觀點(dian),本(ben)網(wang)(wang)亦不對其(qi)(qi)真實(shi)性(xing)負(fu)責(ze),持異議者應與(yu)原(yuan)出(chu)處單位主張權(quan)利。
特別鏈接:政府部門交易機構證券期貨四所兩司新聞發布平臺友情鏈接版權聲明
關于報社關于本站廣告發布免責條款
中國證券報社版權所有,未經書面授權不得復制或建立鏡像 經營許可證編號:京B2-20180749 京公網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved
中(zhong)國(guo)證券報社(she)版權所有,未經書面授(shou)權不(bu)得復制或建立鏡像
經營許可證(zheng)編號:京B2-20180749 京公網(wang)安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved